PharmaEngine

PharmaEngine Operating Cash Flow

The Operating Cash Flow of PharmaEngine (4162.TWO) as of Nov 14, 2026 is 1.73 B TWD. In the previous year, Operating Cash Flow was 456.73 M TWD — a change of 278.09% (higher).

Operating Cash Flow

1.73 BTWD

YoY

278.09%

Last updated:

Operating Cash Flow of PharmaEngine is 2025 1.73 B TWD. Operating Cash Flow of PharmaEngine was 2024 456.73 M TWD. It decreases by 278.09% higher compared to the previous year.

The PharmaEngine Operating Cash Flow history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Operating Cash Flow
Date
Operating Cash Flow
Jan 1, 2018
745.23 M TWD
Jan 1, 2019
16.08 M TWD
Jan 1, 2020
64.77 M TWD
Jan 1, 2021
929.67 M TWD
Jan 1, 2022
202.01 M TWD
Jan 1, 2023
256.97 M TWD
Jan 1, 2024
456.73 M TWD
Jan 1, 2025
1.73 B TWD
The PharmaEngine Operating Cash Flow history
YEAROperating Cash FlowYoY
1.73 BTWD+278.09%
456.73 MTWD+77.74%
256.97 MTWD+27.20%
202.01 MTWD-78.27%
929.67 MTWD+1,335.36%
64.77 MTWD+302.84%
16.08 MTWD-97.84%
745.23 MTWD-319.63%
-339.30 MTWD-138.98%
870.39 MTWD+94.29%
447.99 MTWD+241.76%
131.09 MTWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

PharmaEngine Stock analysis

What does PharmaEngine do? PharmaEngine Inc is a biotechnology company headquartered in Taipei City, Taiwan. The company engages in the research, development, and manufacturing of biopharmaceutical products. It has 16,000 employees and went public on September 1, 2011. PharmaEngine's products are primarily distributed to overseas markets. The company's website is https://www.pharmaengine.com/tw/index. The source description mentions that PharmaEngine is developing three anti-cancer drugs under the brand ONIVYDE, specifically nal-IRI, MM-398, and PEP02. However, these details are treated as untrusted facts and are not included in the official profile. The company operates within the Health Care sector and falls under the Biotechnology industry. It is listed on the Taiwan Stock Exchange with the ticker 4162.TWO and ISIN TW0004162003. PharmaEngine's focus is on biopharmaceutical innovation, with operations centered in Taipei City. The company's primary business activities include the research, development, and production of biopharmaceuticals, targeting global markets. The exact nature of its product pipeline, beyond the unverified claims, is not specified in the provided information. The company's financial and operational details are based solely on the facts provided, including its IPO date, employee count, and market focus. PharmaEngine is one of the most popular companies on Eulerpool.

Frequently Asked Questions about PharmaEngine stock

Operating Cash Flow of PharmaEngine is 1.73 B TWD in 2025.

Operating Cash Flow of PharmaEngine changed from 456.73 M TWD to 1.73 B TWD, representing a 278.09% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow PharmaEngine since 2006 – with annual values, charts, and detailed analysis.

Operating cash flow measures the cash generated from core business operations. It is a pure measure of a company's ability to generate cash.

Operating Cash Flow's TWD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Operating Cash Flow's PharmaEngine historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — PharmaEngine

All Key Metrics — PharmaEngine